长春高新(000661.SZ)：子公司褪黑素颗粒上市申请获得受理

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), has received the Acceptance Notice from the National Medical Products Administration for the domestic production drug registration application of melatonin granules, a product developed for the pediatric neuropsychiatric field [1] Group 1 - Jinsai Pharmaceutical's melatonin granules are classified as a Class 4 chemical drug [1] - The product aims to improve sleep difficulties associated with neurodevelopmental disorders in children [1] - The mechanism of action involves activating the MT1 and MT2 receptors in the suprachiasmatic nucleus to regulate neural activity, demonstrating sleep-inducing effects [1]